Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Company Significantly Reduces Expenses To Pursue Strategic Alternatives While Maintaining Multiple Myeloma Clinical Trial BOSTON, Feb. 3 /PRNewswire-FirstCall/ -- GlycoGenesys, Inc...
GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company, today announced that it requested a hearing before a Nasdaq Listing Qualifications Panel to appeal the Nasdaq Staff...
GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company focused on drug development, today commented on results from its Form 10-Q for the quarter ended September 30, 2005. ? Select Financial...
GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company, today announced it has initiated Roswell Park Cancer Institute, (RPCI) Buffalo, New York as a clinical site for its Phase I/II dose...
GlycoGenesys, Inc. (Nasdaq: GLGS), a biotechnology company, announced today that Frederick E. Pierce, II, VP of Business Development will make a corporate presentation at the Bio-Europe...
GlycoGenesys, Inc.. (Nasdaq: GLGS), a biotechnology company, announced today that John W. Burns, Sr. VP. And CFO will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on...
GlycoGenesys, Inc. (Nasdaq: GLGS), a biotechnology company, today announced it has entered into a common stock purchase agreement with Fusion Capital Fund II, LLC, a Chicago-based institutional...
VANCOUVER, British Columbia, Sept 27 /PRNewswire/ -- ChineseWorldNet.com Inc. is proud to present the third annual Global Chinese Financial Forum (GCFF) -- Toronto Conference 2005 on October...
Data Presented At The XI International Work Shop on Chronic Lymphocytic Leukemia ? GlycoGenesys, Inc., (NASDAQ: GLGS), a biotechnology company, today announced that Dr. Finbarr Cotter...
? GCS-100 Targets Galectin-3 in Multiple Myeloma Cells In Vitro, Leading to Increased Anti-Tumor Activity When Combined With Dexamethasone ? GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
